CNR1 and Parkinson disease: The growing evidence, including changes in cannabinoids, mediated signaling, presence of CBR subtypes in affected brain regions, and changes in ECS in basal ganglia following L-DOPA treatment, support the role of cannabis in the pathogenesis of PD [424,425].